3/9/2010

The FDA set Oct. 16 as its approval deadline for ISTA Pharmaceuticals' XiDay, a once-daily formulation of eye drug Xibrom. Both drugs are indicated for eye inflammation after cataract surgery.

Full Story:
Google

Related Summaries